Clinical research on psychedelics gets a boost from new study: Delphi consensus yields ReSPCT setting reporting guidelines

Psychedelic clinical research gets a boost from a new international study that targets a key reason trials can reach inconsistent results: failure to properly report how a participant’s mindset and surroundings influence effects. A Delphi consensus involving 89 experts from 17 countries produced the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, a 30-item checklist intended to standardize which psychosocial context factors most affect a psychedelic experience. The work is framed as a first global agreement on setting-related reporting priorities. The article notes that context is often treated as noise in conventional psychoactive-drug studies, but ReSPCT instead aims to make context measurable and comparable across trials, supporting replication and clarifying therapeutic potential. It also links the need for better reporting to regulatory scrutiny, mentioning an FDA decision that rejected MDMA-assisted therapy for PTSD in part due to inconsistent trial reporting.